WARRINGTON, Pa., May 1, 2013 /PRNewswire/ -- Discovery Laboratories, Inc. (NASDAQ: DSCO), a specialty biotechnology company dedicated to advancing a new standard in respiratory critical care, today announced the release of two peer-reviewed publications related to AFECTAIR ®, the Company's proprietary aerosol-conducting airway connector designed with the goal of simplifying and improving aerosolized medication delivery to infants requiring mechanical ventilation in the neonatal and pediatric intensive care units.
"Discovery Labs has had a long-standing commitment to presenting our scientific findings through the peer review process, thereby providing the scientific rigor and transparency expected by healthcare professionals today," said Dr. Russell G. Clayton, Senior Vice President, Research & Development, of Discovery Labs. "Our goal is to better inform healthcare professionals about our products and the patients who might benefit from our novel technologies."
The two publications are as follows:
Aerosolized albuterol sulfate delivery under neonatal ventilatory conditions – in vitro evaluation of a novel ventilator circuit patient interface connector - Journal of Aerosol Medicine and Pulmonary Delivery. March 2013, Volume 26, Number 0, 2013, Pages 1-8The goal of this in vitro study, previously presented at the 2012 Hot Topics in Neonatology Annual Meeting, was to characterize the delivery of aerosolized albuterol sulfate, a medication commonly delivered in aerosolized form, under simulated neonatal ventilatory conditions using AFECTAIR. Authors of the study found that use of AFECTAIR resulted in an increased delivery of albuterol sulfate at the patient interface compared with the method currently used to introduce aerosolized medication into the ventilator circuit. In addition, the aerosol characteristics at the patient interface were more consistent with the aerosol characteristics produced by the nebulizer when the aerosolized medication was delivered through AFECTAIR compared with the currently used method. Authors concluded that AFECTAIR may be a useful, new approach for the delivery of aerosolized medications to neonates requiring positive pressure ventilatory support.